Horizon Therapeutics Public Ltd Co
HZNPDelisted Oct 6, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492426
Horizon Therapeutics Public Ltd Co was delisted on Oct 6, 2023; its insiders filed their last Form 4 on Oct 6, 2023; 483 institutions reported holding it in 13F filings for Q3 2023, worth $24.8B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Horizon Therapeutics Public Ltd Co as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
HZNP is no longer listed, and 13F filings after Q3 2023 list far fewer holders. See Q3 2023
- Institutional holders
- 6
- −470 vs. Q3 2023
- Shares held
- 426
- −213.2M (−100.0%) vs. Q3 2023
- Total value
- $49.4K
- −$24.8B (−100.0%) vs. Q3 2023
- New holders
- 2
- 0 more added
- Sold out
- 472
- 1 more reduced
7 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HZNP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $116 |
| Q1 2026 | 1 | $116 |
| Q4 2025 | 1 | $116 |
| Q3 2025 | 1 | $116 |
| Q2 2025 | 1 | $116 |
| Q1 2025 | 1 | $116 |
| Q4 2024 | 1 | $116 |
| Q3 2024 | 1 | $116 |
| Q2 2024 | 2 | $3.95K |
| Q1 2024 | 1 | $116 |
| Q4 2023 | 6 | $49.4K |
| Q3 2023 | 483 | $24.8B |
| Q2 2023 | 516 | $21.7B |
| Q1 2023 | 552 | $22.5B |
| Q4 2022 | 611 | $23.8B |
| Q3 2022 | 528 | $13.0B |
| Q2 2022 | 615 | $16.5B |
| Q1 2022 | 618 | $21.8B |
| Q4 2021 | 609 | $22.0B |
| Q3 2021 | 571 | $22.2B |
| Q2 2021 | 527 | $18.9B |
| Q1 2021 | 516 | $18.4B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Horizon Therapeutics Public Ltd Co; share changes are against Q3 2023.